Abstracts tagged "methotrexate (MTX) and tolerance"

Abstract Number: 544 • 2019 ACR/ARP Annual Meeting
Tolerance, Survival, and Adherence to Methotrexate Treatment in Patients with Rheumatoid Arthritis
Juan Sevillano¹, Dafne Capelusnik ², Emilce Schneeberger ³ and Gustavo Citera ⁴, ¹Instituto de Rehablitacion Psicofisica, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Instituto de Rehabilitacion Psicofisica, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ³Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Methotrexate (MTX) is the most frequently used medication in patients with Rheumatoid Arthritis (RA). However, several authors have questioned its success due to the…
Abstract Number: 1463 • 2017 ACR/ARHP Annual Meeting
Interaction between Methotrexate and BAFF for Preventing Immunization Against TNF-α Inhibitors By Increasing Adenosine and Regulatory B-Cell Subsets
Samuel Bitoun¹, Gaetane Nocturne², Bineta Ly³, Juliette Pascaud⁴, Alain Pruvost⁵ and X Mariette⁶, ¹INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicëtre, France, ²INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicêtre, France, ³INSERM U1184, Paris Sud University, Kremlin Bicetre, France, ⁴U1184 IMVA, Université Paris Sud, Le Kremlin-Bicêtre Cedex, France, ⁵CEA - DRF/iBiTec-S - LabEx LERMIT - MetaboHUB-Paris, Gif sur Yvette, France, ⁶INSERM U1184, Université Paris-Sud, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France
Background/Purpose: TNFα inhibitors (TNFi) can be immunogenic in patients with autoimmune diseases. B-cell activating factor transgenic mice (BAFFtg) are a model of autoimmune disease since…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].